Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies (clinicaltrials.gov) - Nov 2, 2021 - P1; N=55; Active, not recruiting; Sponsor: M.D. Anderson Cancer Center; Trial completion date: May 2021 ➔ May 2024; Trial primary completion date: May 2021 ➔ May 2023
Clinical • Trial completion date • Trial primary completion date • Melanoma • Oncology • Solid Tumor
|